DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
47 hedge funds and large institutions have $3.2M invested in DMK Pharmaceuticals Corporation Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
48% more capital invested
Capital invested by funds: $2.16M → $3.2M (+$1.04M)
2% less funds holding
Funds holding: 48 → 47 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.75M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$62.1K |
| 3 |
HF
HRT Financial
New York
|
+$24.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$16.5K |
| 5 |
Morgan Stanley
New York
|
+$2.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$17K |
| 2 |
Jane Street
New York
|
-$16.4K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$9K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.67K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$638 |
DMK Hedge Fund Activity: Q1 2023 in Review
47 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2023, worth a combined $3.2M — up 48% from $2.16M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of DMK and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.75M. The largest seller was Virtu Financial, exiting entirely with an estimated $17K sold.
- 47 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $3.2M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2023, up 48% quarter-over-quarter.
- 5 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2023 was Armistice Capital, an estimated $2.75M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2023 was Virtu Financial, an estimated $17K sold.
Based on aggregated 13F filings for Q1 2023.